Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Investment analysts at Zacks Research issued their Q3 2025 earnings per share (EPS) estimates for shares of Theravance Biopharma in a research note issued on Tuesday, September 2nd. Zacks Research analyst Team forecasts that the biopharmaceutical company will post earnings per share of ($0.09) for the quarter. Zacks Research has a "Strong-Buy" rating on the stock. The consensus estimate for Theravance Biopharma's current full-year earnings is ($1.09) per share. Zacks Research also issued estimates for Theravance Biopharma's Q4 2025 earnings at $0.22 EPS, FY2025 earnings at $0.94 EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($0.47) EPS, Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.17) EPS.
TBPH has been the subject of several other reports. Wall Street Zen raised Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 16th. BTIG Research upped their price objective on Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a research note on Friday, June 27th. Finally, Jones Trading raised Theravance Biopharma to a "strong-buy" rating and set a $24.00 price objective for the company in a research note on Tuesday, June 17th. Two analysts have rated the stock with a Strong Buy rating and two have given a Buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Strong Buy" and an average target price of $21.33.
Read Our Latest Research Report on Theravance Biopharma
Theravance Biopharma Stock Down 0.7%
Shares of TBPH traded down $0.10 during mid-day trading on Friday, reaching $13.95. The company had a trading volume of 659,988 shares, compared to its average volume of 574,998. The stock has a market capitalization of $702.52 million, a P/E ratio of 58.13 and a beta of 0.04. The stock has a 50 day moving average of $12.12 and a two-hundred day moving average of $10.45. Theravance Biopharma has a 52-week low of $7.88 and a 52-week high of $14.55.
Institutional Investors Weigh In On Theravance Biopharma
A number of institutional investors have recently added to or reduced their stakes in TBPH. Nuveen LLC acquired a new stake in Theravance Biopharma in the first quarter worth approximately $3,348,000. Newtyn Management LLC raised its stake in Theravance Biopharma by 5.7% during the 4th quarter. Newtyn Management LLC now owns 4,757,403 shares of the biopharmaceutical company's stock valued at $44,767,000 after purchasing an additional 258,337 shares during the period. Jefferies Financial Group Inc. grew its holdings in shares of Theravance Biopharma by 1,191.9% during the 2nd quarter. Jefferies Financial Group Inc. now owns 276,887 shares of the biopharmaceutical company's stock valued at $3,054,000 after acquiring an additional 255,455 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Theravance Biopharma by 121,993.7% during the 1st quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company's stock valued at $1,554,000 after acquiring an additional 174,451 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Theravance Biopharma by 20.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company's stock valued at $5,211,000 after acquiring an additional 95,304 shares in the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other Theravance Biopharma news, SVP Rhonda Farnum sold 10,000 shares of Theravance Biopharma stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $11.39, for a total value of $113,900.00. Following the completion of the transaction, the senior vice president directly owned 326,918 shares in the company, valued at $3,723,596.02. The trade was a 2.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 6.90% of the stock is currently owned by corporate insiders.
About Theravance Biopharma
(
Get Free Report)
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
See Also
Before you consider Theravance Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theravance Biopharma wasn't on the list.
While Theravance Biopharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
